Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

• Conditions: Placenta Accreta
• Interventions: Diagnostic Test: Serum alpha-fetoproteine

• Registration Number: NCT04082507
• Lead Sponsor: rasha medhat abdul-hady

Brief Summary

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Detailed Description

in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence of morbid adherent placenta accurately?

Study Timeline

• Study Start: 2017-01-01
• Study First Submitted: 2019-08-29
• Primary Completion: 2019-08-30
• Study Completion: 2019-08-30
• Status Verified: 2019-09
• Study First Submitted QC: 2019-09-06
• Last Update Submitted: 2019-09-06
• Study First Posted: 2019-09-09
• Last Update Posted: 2019-09-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 150

Inclusion Criteria

• pregnant women with history of scarred uterus

  • plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S
  • Gestational age from 28wks to full term

Exclusion Criteria

• pregnant women with fetus with congenital anomalies

  • pregnant women with ovarian swelling
  • pregnant women with medical disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Adherent placenta	Serum alpha-fetoproteine	placenta dosenot separated within 15 minutes after delivery of fetus

Primary Outcome Measures

Name	Time	Method
Maternal serum alpha-fetoprotein	From 28weeks to 37 weeks	ng/ml or MOM(Multiple of the median)

Trial Locations

Locations (1)

Ain shams university maternity hospital; 🇪🇬 Cairo, Egypt